This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Francia, G. Articles by Hart, I. R. Search for Related Content PubMed PubMed Citation Articles by Francia, G. Articles by Hart, I. R.

Identification by Differential Display of Annexin-VI, a Gene Differentially Expressed during Melanoma Progression

Richard Dimbleby Department of Cancer Research/Imperial Cancer Research Fund, The Rayne Institute, United Medical and Dental Schools, St. Thomas' Hospital, Lambeth Palace Road, London SE1 7EH [G. F., S. D. M., J. F. M., I. R. H.]; Department of Physiology, University College London, Gower Street, London WC1E 6BT [S. E. M.]; and Histopathology Unit, Imperial Cancer Research Fund, Lincoln's Inn Fields, London WC2A 3PX [A. M. H.], United Kingdom

To identify genes involved in the melanocyte to malignant melanoma conversion, we have applied differential display to the comparison of syngeneic murine B16F10 (metastatic melanoma) and Melan-a-immortalized melanocyte cell lines. Approximately 7000 bands were analyzed, revealing approximately 80 to be differentially displayed. Reverse Northern blotting and subsequent Northern blotting confirmed the reproducible differential expression of four transcripts. Three B16F10-specific bands encode novel genes or partially sequenced cDNAs of unknown function. One Melan-a-specific band was found to be identical to the 3' end region of the mouse Annexin VI mRNA and shown to have a reduced message expression in B16F10 relative to Melan-a. Differential expression was confirmed at the protein level with Western blotting using a rabbit polyclonal antiserum. Immunohistochemistry of human melanoma specimens with this antiserum revealed a decrease or loss of Annexin VI expression as melanomas progressed from a benign to a more malignant phenotype. Our results provide further evidence for a potential role of Annexin VI in tumor suppression.

¹ To whom requests for reprints should be addressed. Phone: 0171-928-9292, ext. 3040; Fax: 0171-922-8216.

Received 6/ 3/96. Accepted 7/16/96.

This article has been cited by other articles:

				A. J. Mutsaers, G. Francia, S. Man, C. R. Lee, J. M.L. Ebos, Y. Wu, L. Witte, S. Berry, M. Moore, and R. S. Kerbel Dose-Dependent Increases in Circulating TGF-{alpha} and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent Clin. Cancer Res., April 1, 2009; 15(7): 2397 - 2405. [Abstract] [Full Text] [PDF]

				J. M. du Manoir, G. Francia, S. Man, M. Mossoba, J. A. Medin, A. Viloria-Petit, D. J. Hicklin, U. Emmenegger, and R. S. Kerbel Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts Clin. Cancer Res., February 1, 2006; 12(3): 904 - 916. [Abstract] [Full Text] [PDF]

				L. Cheval, J. P. Duong Van Huyen, P. Bruneval, J.-M. Verbavatz, J.-M. Elalouf, and A. Doucet Plasticity of mouse renal collecting duct in response to potassium depletion Physiol Genomics, September 16, 2004; 19(1): 61 - 73. [Abstract] [Full Text] [PDF]

				G. Bocci, S. Man, S. K. Green, G. Francia, J. M. L. Ebos, J. M. du Manoir, A. Weinerman, U. Emmenegger, L. Ma, P. Thorpe, et al. Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies Cancer Res., September 15, 2004; 64(18): 6616 - 6625. [Abstract] [Full Text] [PDF]

				G. Francia, S. Man, B. Teicher, L. Grasso, and R. S. Kerbel Gene Expression Analysis of Tumor Spheroids Reveals a Role for Suppressed DNA Mismatch Repair in Multicellular Resistance to Alkylating Agents Mol. Cell. Biol., August 1, 2004; 24(15): 6837 - 6849. [Abstract] [Full Text] [PDF]

				J. M. Garcia Pedrero, M. P. Fernandez, R. O. Morgan, A. Herrero Zapatero, M. V. Gonzalez, C. Suarez Nieto, and J. P. Rodrigo Annexin A1 Down-Regulation in Head and Neck Cancer Is Associated with Epithelial Differentiation Status Am. J. Pathol., January 1, 2004; 164(1): 73 - 79. [Abstract] [Full Text] [PDF]

				G. Bocci, G. Francia, S. Man, J. Lawler, and R. S. Kerbel Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy PNAS, October 28, 2003; 100(22): 12917 - 12922. [Abstract] [Full Text] [PDF]

				P.M. Brett, M. Parkar, I. Olsen, and M. Tonetti Expression Profiling of Periodontal Ligament Cells Stimulated with Enamel Matrix Proteins in vitro: A Model for Tissue Regeneration Journal of Dental Research, November 1, 2002; 81(11): 776 - 783. [Abstract] [Full Text] [PDF]

				R. Neef, M. A. Kuske, E. Prols, and J. P. Johnson Identification of the Human PHLDA1/TDAG51 Gene: Down-Regulation in Metastatic Melanoma Contributes to Apoptosis Resistance and Growth Deregulation Cancer Res., October 15, 2002; 62(20): 5920 - 5929. [Abstract] [Full Text] [PDF]

				S.-H. Liu, C.-Y. Lin, S.-Y. Peng, Y.-M. Jeng, H.-W. Pan, P.-L. Lai, C.-L. Liu, and H.-C. Hsu Down-Regulation of Annexin A10 in Hepatocellular Carcinoma Is Associated with Vascular Invasion, Early Recurrence, and Poor Prognosis in Synergy with p53 Mutation Am. J. Pathol., May 1, 2002; 160(5): 1831 - 1837. [Abstract] [Full Text] [PDF]

				V. Gerke and S. E. Moss Annexins: From Structure to Function Physiol Rev, April 1, 2002; 82(2): 331 - 371. [Abstract] [Full Text] [PDF]

				T. E. Hawkins, J. Roes, D. Rees, J. Monkhouse, and S. E. Moss Immunological Development and Cardiovascular Function Are Normal in Annexin VI Null Mutant Mice Mol. Cell. Biol., December 1, 1999; 19(12): 8028 - 8032. [Abstract] [Full Text] [PDF]

				M. Custer, B. Spindler, F. Verrey, H. Murer, and J. Biber Identification of a new gene product (diphor-1) regulated by dietary phosphate Am J Physiol Renal Physiol, November 1, 1997; 273(5): F801 - F806. [Abstract] [Full Text] [PDF]